New drug trial targets advanced lung cancer with genetic marker
NCT ID NCT04395677
Summary
This study is testing a new drug called AB-106 for people with advanced non-small cell lung cancer that has a specific genetic change called ROS1 fusion. The goal is to see if the drug is safe and effective at controlling the cancer. Participants take the drug daily in repeating cycles until their cancer progresses.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.